circulation, whereas maternal insulin is unable to cross the placental barrier. 9, 10 Consequently, GDM-induced maternal hyperglycemia leads to endothelial dysfunction in the fetal micro-and macrocirculation, [10] [11] [12] fetal hyperglycemia and chronic hyperinsulinemia, ultimately producing adverse long-term consequences for the child, who is more susceptible to developing type 2 DM and cardiovascular disease. 10 It has been suggested that, similar to observations in adult diabetic patients, GDM induces fetal endothelial cell (EC) dysfunction. [13] [14] [15] The persistence of the phenotypic and molecular changes induced by GDM in utero might be responsible for the increased cardiovascular and type 2 DM risk in children. 12 In line with this hypothesis, in vivo or in vitro exposure to high d-glucose (HG) levels induces epigenetic changes that negatively affect endothelial function. 16 Differently from epigenetic factors, which modulate gene transcription, microRNAs (miRs) are a class of small, noncoding RNAs that regulate gene expression at the post-transcriptional level. Each miR acts on several target messenger RNAs (mRNAs), which are mostly recognized through semicomplementary oligonucleotide sequences in the miR seed sequence (≈8 nucleotides) and the 3′-untranslated region of the mRNA. 17 MiRs control vascular development, function, and disease. 17 Moreover, there is an accumulating evidence that DM-associated miR deregulation has negative functional consequences on the endothelium. 18, 19 MiRs and components of the epigenetic machinery have been shown to be reciprocally regulated. 20 Indeed, several examples of mutual regulation between miRs and their target genes have also been reported. 21 MiR-101 is known to affect endothelial function and angiogenesis under normal glucose conditions 22 and to target the histone methyltransferase enhancer of zester homolog 2 (EZH2) for inhibition. 22, 23 EZH2 is part of the polycomb repressor complex 2, a multisubunit complex, which initiates and maintains the trimethylation of histone H3 on lysine 27(H3K27me3), an epigenetic mark associated with heterochromatin formation and gene silencing. 24, 25 We have previously shown that the EZH2 locus generates, by alternative splicing, 2 different isoforms, EZH2-α and EZH2-β, both localized to the cell nucleus, able to generate the polycomb repressor complex 2 , and to regulate the H3K27 methylation. 26 The different isoforms can each not only regulate distinct targets but also share gene expression networks, making the regulation of transcription based on the deposition of the H3K27 histone mark more complex than previously anticipated. 26 Recent studies suggest that EZH2 regulates angiogenesis 22 ,23,27-30 although the molecular mechanisms underlying this event are still under intensive investigation. To the best of our knowledge, the regulation of EZH2 by miRs, in the context of DM, is still unexplored. Here, we provide the first evidence that exposure to a diabetic intrauterine environment alters fetal EC function in association with increased miR-101 levels and decreased EZH2 expression in human umbilical vein ECs (HUVECs), which are of fetal origin. We observed that a particular EZH2 isoform, EZH2β, is reduced in GDM-HUVECs. MiR-101 inhibition improves functional capacity and restores the level of EZH2 in GDM-HUVECs and in HG-stimulated control HUVECs in vitro. Moreover, our data suggest that EZH2 binds to the miR-101 locus, resulting in trimethylation of H3K27 and transcriptional inhibition. This epigenetic regulatory response is blunted by HG and in HUVECs from GDM pregnancies, potentially contributing to a fetal endotheliopathy, which could favor the appearance of cardiovascular disease in the offspring of mothers with GDM. Thus, our data provide the evidence implicating miR-101 and EZH2 in regulating fetal EC functions in the context of GDM. Because miR inhibitors are in clinical trials, our findings not only have mechanistic importance but also should be considered for the future development of potential therapies aimed at washing out the epigenetic imprinting of a GDM pregnancy from the offspring vasculature.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

GDM Induces Phenotypic Alterations in HUVECs
Flow cytometry for the endothelial marker CD31 confirmed the endothelial phenotype of HUVECs from both healthy (control) and GDM-complicated pregnancies. In fact, ≥95% of GDM-HUVECs and healthy HUVECs were CD31 positive (data not shown). In comparison with healthy HUVECs controls, GDM-HUVECs showed an increased rate of apoptosis ( Figure 1A ), a lower proliferative index after stimulation with fetal bovine serum ( Figure 1B ), a reduced capacity to form cellular networks on Matrigel ( Figure 1C) , and an impaired migration capacity (measured using a scratch assay) ( Figure 1D ). These GDM-induced phenotypic alterations were observed after 5 to 6 passages in GDM-HUVECs cultured under normal d-glucose conditions, which suggests that they likely mimic long-term effects of the GDM-induced in utero environment.
Exposure to HG Impairs Survival and Functional Capacity of Control HUVECs
The deleterious effects of HG on cultured HUVECs have been widely reported. [31] [32] [33] To seek confirmation of these effects, in our own experimental system, cultured healthy HUVECs were exposed to 2 different concentrations of increased d-glucose: 25 or 12.5 mmol/L for 12 to 48 hours. Normal d-glucose (5 mmol/L) was combined with 20 mmol/L of l-glucose and used as an osmotic control. Figure  I in 
GDM Is Associated With Increased MiR-101 Expression That Affects HUVECs Survival and Functional Capabilities
MiR-101 expression was higher in GDM-HUVECs when compared with healthy HUVECs (Figure 2A) .To elucidate the effect of miR-101 on GDM-HUVECs survival and angiogenic capacities, we altered intracellular miR-101 levels by transfecting with pre-miR-101 (to increase the miR-101 expression) or anti-miR-101 (to inhibit miR-101 expression), or a scramble sequence as control. We used healthy HUVECs transfected with scramble for reference. Figure 2B shows miR-101 changes in response to successful transfection. We found that anti-miR-101 exerted an antiapoptotic effect on GDM-HUVECs ( Figure 2C ). By contrast, the proliferation capacity of GDM-HUVECs was unresponsive to the forced miR-101 expressional changes ( Figure 2D ). Although an antiangiogenic property of miR-101 on normal HUVECs has already been reported, 22, 23 its effect on GDM-HUVECs remained to be investigated. We observed that anti-miR-101 restored the GDM-HUVEC functional angiogenic capacity, measured as capillary-like tube formation on Matrigel ( Figure 2E ). Moreover, pre-miR-101 reduced the migratory capacity in GDM-HUVECs, whereas anti-miR-101 elicited no effect ( Figure 2F ). Phenotypic characterization of human umbilical vein endothelial cells (HUVECs) isolated from umbilical cords obtained at child delivery after gestational diabetes mellitus (GDM) or normal pregnancies. HUVECs were extracted from the umbilical cord veins obtained at delivery from GDM mothers and healthy control mothers and were expanded for 5 to 6 passages in vitro. In comparison with healthy HUVECs, GDM-HUVECs showed increased apoptosis rate (assessed using a Cell Death Detection ELISA and expressed as normalized absorbance units; A) and an impaired capacity to proliferate (assessed by 5-bromo-2'-deoxyuridine [BrdU] incorporation assay. The BrdU assay was performed on HUVECs starved of fetal bovine serum (FBS) for 1 hour and then either returned or not to normal culture conditions. The proliferative response has been calculated by the ratio between the BrdU incorporation values in the FBS-starved and in normal conditions; B). Moreover GDM-HUVECs showed an impaired capacity to form networks on Matrigel (C) and to migrate and close a gap in a scratch assay (Scale bar, 0.5 mm; D). All data are presented as mean±SEM. *P<0.05, **P<0.01, and ***P<0.001 vs healthy-HUVECs group. The number of donors used to prepare the tested HUVECs is reported in each panel.
EZH2 Is Downregulated in GDM-HUVECs
MiR-101 reportedly targets EZH2 for inhibition. 20, 21, 27 Consistently, the mRNA levels of EZH2 were reduced in GDM-HUVECs in comparison with control healthyHUVECs ( Figure 3A) . Interestingly, we noticed that the EZH2-β isoform was decreased in GDM-HUVECs, whereas Gestational diabetes mellitus (GDM) is associated with expressional changes in microRNA-101 (miR-101) that affect the survival and angiogenic capacities of human umbilical vein endothelial cells (HUVECs). The relative expression of miR-101 (normalized to small nuclear ribonucleic acid 6 -snU6-) is higher in GDM-HUVECs when compared with that in healthy HUVECs (A). GDM-HUVECs were transfected with a precursor (pre-miR-101), inhibitor (anti-miR-101), or a scramble control (GDM-SCR) to modulate miR-101 expression levels. Healthy HUVECs transfected with scramble control were used as reference (healthy-SCR). The relative expression of miR-101 in GDM-HUVECs was shown to be correctly altered (B). Anti-miR-101 reduced the relative apoptotic activity in GDMHUVECs (C), but it did not affect cell proliferation (D). The angiogenic capacity of GDM-HUVECs (measured by network formation on Matrigel) was improved by anti-miR-101 (E). Pre-miR-101 reduced the migratory capacity (expressed, in mm 2 /h, as the velocity of reendothelization of the wounded area), whereas anti-miR-101 elicited no effect (F). E and F, Scale bar, 0.5 mm. All data are expressed as mean±SEM. *P<0.05 and **P<0.01 vs healthy-SCR; †P<0.05 vs GDM-SCR. The number of donors used to prepare the tested HUVECs is reported in each panel.
the EZH2-α level was unchanged ( Figure 3A ). EZH2 protein levels were also reduced in GDM-HUVECs when compared with that in healthy HUVECs ( Figure 3B ). Accordingly, the trimethylation of histone H3 on lysine 27 modification that reflects the function of EZH2 enzymatic activity was also decreased ( Figure 3C ). To clarify the role of EZH2 isoforms on H3K27 trimethylation in GDM-HUVECs, we separately overexpressed each form by using adenovirus (Ad)-based transductions. An Ad carrying an empty vector (Ad-Null) was used as control. Figure II in the online-only Data Supplement confirmed increased mRNA and protein levels of EZH2-α and EZH2-β after gene transfer. We observed that in GDMHUVECs, Ad.EZH2-β increased the H3K27me3 levels (in comparison with Ad.Null), whereas Ad.EZH2-α did not ( Figure 3D ).
Mir-101 Downregulates EZH2 Expression in GDM-HUVECs
In line with the hypothesis that miR-101 directly targets EZH2 for inhibition in GDM-HUVECs, we found that both premiR-101 and anti-miR-101 affected EZH2 mRNA expression ( Figure 4A ). When looking specifically at the effect of antimiR-101 on each of the 2 EZH2 isoforms, we found that both were increased ( Figure 4B ). In addition, pre-miR-101 decreased EZH2 protein ( Figure 4C ) and trimethylation of histone H3 on lysine 27 ( Figure 4D ) expression. Finally, anti-miR-101 Figure 3 . The enhancer of zester homolog-2 (EZH2) is downregulated in gestational diabetes mellitus-human umbilical vein endothelial cells (GDM-HUVECs). The relative mRNA levels of total EZH2 and EZH2-β were reduced in GDM-HUVECs in comparison with healthy HUVECs, whereas the relative expression of EZH2 α was not (A). EZH2 protein expression was also reduced in GDM-HUVECs (measured Western blotting, with blot densitometry normalized to lamin A/C; B). Accordingly, trimethylation of histone H3 on lysine 27 (H3K27me3), derived by EZH2 enzymatic activity, was decreased in GDM-HUVECs (Western blotting, with blot densitometry normalized to H3; C). Adenovirus (Ad)-induced EZH2-β overexpression increased H3K27me3 levels in GDM-HUVECs, whereas Ad.EZH2 α was ineffective (D). All data are presented as mean±SEM. *P<0.05 vs healthy HUVECs; +P<0.05 vs Ad.Null and ɅP<0.05 vs Ad.EZH2-α in GDM-HUVECs. The number of donors used to prepare the tested HUVECs is reported in each panel.
increased EZH2 in GDM-HUVECs ( Figure 4C ), but it did not change the overall H3K27me3 expression ( Figure 4D ).
GDM Reduces EZH2 and H3K27me3
Occupancy at the miR-101 Locus Transcriptional Regulatory Region EZH2 has been previously proposed to regulate miR-101 in non-ECs. 21 Notably, as described above, we here provide new evidence that miR-101 regulates EZH2 in GDM-HUVECs. We also hypothesized that EZH2 is required for the silencing of miR-101 expression and that lower EZH2-β levels found in GDM-HUVECs may contribute to explain the increased miR-101 levels found in these cells. Consequently, to further characterize the mechanisms by which EZH2 regulates miR-101 in HUVECs, we looked at EZH2 and H3K27me3 occupancy within the promoter of the miR-101 locus. A scheme of the miR-101 promoter is presented as Figure 5A . By performing chromatin immunoprecipitation with antibodies targeting EZH2 and H3K27me3, followed by polymerase chain reaction for different miR-101 promoter regions (Table II in the online-only Data Supplement), we found that EZH2 and H3K27me3 occupy the miR-101 promoter in both healthy HUVECs and GDM-HUVECs ( Figure 5B and 5C) . Moreover, in GDM-HUVECs, we observed decreased EZH2
and H3K27me3 occupancy at a regulatory sequence beginning −396 bp upstream of the transcriptional start site ( Figure 5B and 5C). Taking into consideration current paradigms, it is expected that reduced EZH2 occupancy on the miR-101 promoter results in a higher accessibility of chromatin, thereby increasing miR-101 transcription in GDM-HUVECs.
EZH2 β Inhibits miR-101 Transcription in HUVECs
In line with the data above, we found increased miR-101 expression after EZH2 silencing in GDM-HUVECs (Figures 5D). To complement these studies, we performed luciferase reporter assays on healthy HUVECs overexpressing either EZH2-α or EZH2-β. Figure 5E shows that Ad-mediated EZH2-β overexpression inhibits the transcriptional activity of the miR-101 promoter. Taken together, these results suggested that in HUVECs miR-101 transcription is regulated by EZH2, in particular by the EZH2-β isoform.
In Vitro Exposure of Control HUVECs to HG Lowers EZH2 Binding to the miR-101 Promoter and Increases miR-101 Expression
Next, we wanted to investigate whether exposure of normal HUVECs to HG in vitro may recapitulate the molecular changes observed in HUVECs from GDM pregnancies. To this end, healthy HUVECs were exposed to HG or normal glucose concentration (with osmotic control) for 48 hours. Chromatin immunoprecipitation-quantitative polymerase chain reaction was used to measure EZH2 binding to the aforementioned miR-101 promoter region beginning at around −396 bp upstream of the transcriptional start site. Indeed, similar to GDM, we found that in vitro exposure to HG reduced the presence of EZH2 at this miR-101 promoter regulatory region ( Figure 6A ). Moreover, congruent with the results form chromatin immunoprecipitation assays, HG increased miR-101 levels in healthy HUVECs ( Figure 6B ). Taken together, our data suggest that EZH2 and miR-101 are reciprocally regulated in HUVECs and that an imbalance of this equilibrium in response to either in vivo GDM or in vitro exposure to HG might result in a lower EZH2 occupancy of the miR-101 locus, thus leading to increased miR-101 transcription and further phenotypic alterations of ECs.
Effect of EZH2 Overexpression on Phenotypic Alterations in GDM-HUVECs
To see whether restoring EZH2 levels in GDM-HUVECs could rescue the cell survival and functional capabilities, we used Ad.EZH2-α or Ad.EZH2-β (control: Ad.Null). Ad.EZH2-β decreased the relative apoptotic activity ( Figure 7A ) and increased the migratory capacity ( Figure 7C ) of GDMHUVECs. In contrast, this treatment did not rescue impaired proliferation ( Figure 7B ) and tube formation ( Figure 7D ) of GDM-HUVECs. Ad.EZH2-α did not alter the behavior of ; Ch1: 65 532 191) derived from the University of California, Santa Cruz (UCSC) genome Browser GRCh37/ hg19 is given in A. Chromatin immunoprecipitation followed by polymerase chain reaction showed that EZH2 occupancy on transcriptional regulatory region (−396/+3 bp from TSS) of the miR-101 promoter was reduced in GDM-HUVECs (B), and consistently also trimethylation of histone H3 on lysine 27 (H3K27me3) binding to this promoter region was decreased in GDM-HUVECs (C). B and C, IgG was used as a negative control. Data were calculated as % bound/input. Relative miR-101 expression level increased in GDM-HUVECs transfected with small interfering RNA for EZH2 (siRNA-EZH2) compared with cells transfected with a scramble sequence (control-siRNA; D). A transcription reporter assay performed in healthy HUVECs showed a significant decrease of miR-101 promoter activity after Ad-mediated EZH2-β overexpression (in comparison with Ad.Null; E). For each experiment, we tested HUVECs from n=3 donors per groups and in triplicate. All data are expressed as mean±SEM. #P<0.05 vs. healthy HUVECs; *P<0.05 vs control siRNA; *P<0.05 vs Ad.Null and ɅP<0.05 vs Ad.EZH2α. Figures 7A-7D ). Taken together, these data suggest that a deficit in EZH2-β contribute to some of the functional defects induced by GDM in fetal ECs.
GDM-HUVECs (
Discussion
Endothelial dysfunction is a common feature in many diseases of pregnancy, as well as under the different forms of DM. In particular, fetal endothelial dysfunction is involved in the abnormal fetal development and growth caused by GDM, and it might be responsible for the increased cardiovascular risk and incidence of type 2 DM observed later in life in the offspring from GDM mothers. 10, 11 Large-scale clinical trials and epidemiological studies of type 1 and type 2 DM patients have revealed that the exposure to prolonged hyperglycemia leaves a long-lasting impression on vascular cells and progressively induces the development of vascular complications, which persist after glycemic control is achieved. 34 Nonetheless, the same studies also demonstrated that good glycemic control can delay the onset of diabetic vascular complications. 35 Both lines of evidence are compatible with an underlying implication of epigenetic mechanisms. The epigenome is a complex system, which shapes the chromatin conformation of the different loci, thus ultimately profoundly affecting gene transcription. Epigenetic modifications allow cells and organisms to respond to changing internal and environmental stimuli and additionally confer the ability of the cell to memorize these environmental situations. According to an early definition, epigenetics is associated with chromatin changes, which were transmitted from parents to offspring. However, this concept has been revisited and it is now suggested that epigenetic changes have a longlasting effect, which can be transmitted at cell division, but that are not necessary perpetual. In other words, the epigenetic modifications (and their transcriptional result), once written, can still be diluted and possibly erased over time under particular circumstances, such as with the use of drugs or lifestyle changes. 36 The concept of a changeable epigenetic status is important because it confers therapeutic hope at different stages of prenatal and postnatal life. Several laboratories, including ours, have hypothesized that well-targeted epigenetic drugs will be one of the big things of future medicine. Before we can reach the stage of designing optimal agents, we should note that the pattern of specific chromatin modifications in vascular ECs under hyperglycemia (as well as different adverse environmental conditions) is not as yet fully understood and necessitates more research. Human vascular ECs reportedly respond to even weak or transient increases in glucose concentration by changing their chromatin status, which results in altered gene expression. 37 Histones are important regulators of the chromatin status. In vascular ECs, the H3 has been reported to be particularly responsive to in vitro exposure to high glucose. 37 Different H3 modifications have been shown to command either transcriptional inhibition or activation. 36 A balance of these H3 modifications, together with other regulatory systems (including transcription factors and some classes of long noncoding RNAs) acting at gene promoters, contributes to the switching on or off of transcription under physiological and pathological conditions. Additional layers of gene expression regulation include miRs, which act by post-transcriptional inhibition of their targeted mRNAs. 38 HUVECs represent a good cell model allowing for noninvasive analyses of the effect of the uterine environment on the fetal endothelium. For instance, molecular abnormalities, especially in the nitric oxide production machinery and the adenosine transport system, have been described in HUVECs from GDM pregnancies. 38, 39 However, to the best of our knowledge, our study has provided a functional characterization of the effect of GDM on HUVECs. In fact, here, we report that cultured GDM-HUVECs demonstrated decreased survival and functional capacity in comparison with HUVECs obtained from healthy nondiabetic mothers who gave birth at the same obstetric unit. Notably, these analyses were performed after cells were expanded in normal d-glucose concentrations for 5 to 6 passages, suggesting that the cells were still affected by the chronic hyperglycemia sensed in utero, which is consistent with the existence of a metabolic memory or legacy. Moreover, we have identified a novel underlying mechanism involving miR-101 and EZH2, the catalytic subunit of the polycomb repressor complex 2 in GDM-elicited endothelial dysfunction. In particular, we have identified that in HUVECs, EZH2 is both a target of, and a transcriptional repressor for, miR-101. Moreover, we have shown that among the 2 recently identified EZH2 isoforms, 26 EZH2-β is the only one which is both a target of GDM and a mediator of some of the GDM damaging effects on HUVECs.
Next, we have used chromatin immunoprecipitation-polymerase chain reaction to provide evidence that EZH2 targets the miR-101 promoter for inhibition in HUVECs, and that this mechanism is impaired in both HUVECs from GDM pregnancies and in HUVECs exposed to HG in culture. In fact, our data suggest that increased miR-101 expression in both GDM-HUVECs and HG-HUVECs is associated with reduced EZH2 binding at transcriptional regulatory regions of the miR-101 gene promoter and reduced H3K27 methylation (within 0.5 kb of transcription starting site), which should result in higher accessibility to transcription factors and consequently to increased miR-101 transcription.
In line with the knowledge that miRs and their target genes are often linked in a regulatory feedback loop, which maintains their homeostatic expressional balance, 18, 20 we propose a model where miR-101 is both a transcriptional target and a post-transcriptional inhibitor of EZH2 in HUVECs. In GDM-HUVECs, miR-101 transcription seems regulated by EZH2-β, only. We have been the first to detect diabetesinduced changes in the levels of miR-101 and EZH2. A recent report indicated a proangiogenic role for EZH2 in HUVECs 20, 25 and identified 946 genes upregulated ≥2-fold because of EZH2 knockdown, 27 in accordance with the EZH2 transcriptional repressive function. Importantly, many of these EZH2-targeted genes are implicated in endothelial dysfunction and cardiovascular disease, 27 which is in line with the hypothesis that a decrease in EZH2 may confer an increased cardiovascular risk profile in the offspring from pregnancies complicated by GDM. If validated in population studies allowing for the follow-up of the children to maturity, this could help scientists understand whether there is any association between what is sensed in HUVECs and the incidence of vascular diseases. Moreover, in future studies, it would be worth attempting to correlate miR-101 and EZH2 levels in HUVECs with the glucose levels in the maternal Figure 7 . Effect of enhancer of zester homolog-2 (EZH2) on survival and functional capacities of gestational diabetes mellitus-human umbilical vein endothelial cells (GDM-HUVECs). GDM-HUVECs were infected with adenovirus carrying EZH2-α, EZH2-β, or an empty vector (Ad.Null). Ad.EZH2 β rescued GDM-HUVEC survival (A) and showed no effect on cell proliferation (B). Moreover, Ad.EZH2 β improved the migration capacity of GDM-HUVECs (C), whereas it exerted no effect on tube formation (presented here as tube length; D). In all tests, Ad.EZH2 β produced similar effect as Ad.Null. C and D, Scale bars, 0.5 mm. Data are presented as mean±SEM. *P<0.05 vs Ad.Null. The number of donors used to prepare the tested HUVECs is reported in each panel.
and fetal blood. In addition, we correlate the level of miR-101 in the HUVECs and the mother's blood at different stages of pregnancy. This could lead to the development of miR-101 as a circulating marker of fetal endothelial damage induced by GDM.
We recently found that increased EZH2 after hypoxia and in vivo limb ischemia in mice negatively controls the angiogenic response and that EZH2 targets 2 proangiogenic genes for transcriptional repression. 30 We also showed that Ad-mediated EZH2-α overexpression impairs the angiogenic capacity of healthy HUVECs in vitro. 30 The results of our 2 studies can be reconciled if we speculate that hypoxia/ischemia and HG/GDM regulate different EZH2 isoforms and other RNAbinding molecules in ECs and that changes in EZH2-α and EZH2-β expression differently affect gene regulation.
Our data show that GDM increases miR-101 in fetal ECs and additionally alters the homeostatic regulatory feedback loop between EZH2 and miR-101. The altered miR-101/ EZH2 equilibrium could continue to influence vascular gene expression and function well after birth. Our data also suggest that some defects of GDM are mediated by miR-101 independently of EZH2. In fact, although miR-101 inhibition rescues most of the studied cell functions in GDM-HUVECs, Ad-mediated EZH2-β only improved the cell survival and migration. MiR-101 acts post-transcriptionally on multiple target genes, including EZH2 and vascular endothelial growth factor A 40 . We did not find vascular endothelial growth factor A expression in HUVECs to be altered by GDM (data not shown). A possible limitation of our study is that we have not identified all the miR-101 target genes, which are involved with the GDM-induced vascular defects. Moreover, because EZH2 regulates the transcription of many different genes, the rescue effect of EZH2-β can be mediated by the inhibition of a plethora of damaging genes.
A recent study has analyzed the methylation profile of placenta and cord blood and described DNA methylation differences between GDM and healthy pregnancies, 41 but this study has not selectively worked on ECs. A more extended profiling of epigenetic modifications should be performed and linked to follow-up data. These studies would help understand whether epigenetic changes in HUVECs could be developed as predictive biomarkers of future vascular disease, in line with the concept of personalized medicine through risk-stratified monitoring and treatment guided by biomarkers. It would be also important to understand (and develop a marker allowing understanding) at what phase of the GDM pregnancy these changes on the fetal endothelium start developing to better design the timing for initiating possible therapeutic interventions. With the focus on the observed changes in EZH2 levels, it would appear conceivable to target miR-101 for inhibition in GDM. MiR targeting drugs are becoming increasingly appealing for clinical translation. Consequently, it is conceivable to hypothesize that miR-101 inhibition at a certain phase of pregnancy, or soon after birth, could be exploited to restore normal EZH2 levels in the endothelium of the fetus or child.
Large population studies suggest that glycemic control can improve, but not reverse, the metabolic memory, which increases cardiovascular risk in individuals previously exposed to hyperglycemia. Histone covalent modifications affect the chromatin architecture, thus making a gene more or less accessible to the transcription machinery. MicroRNAs represent a different regulatory layer of gene expression, acting posttranscriptionally on their targeted messenger RNAs. Gestational diabetes mellitus is associated with a higher risk of cardiovascular disease in the offspring. Mechanistic studies are urgently needed to design therapeutic interventions. Here, we propose fetal umbilical cord vein endothelial cells as a noninvasive cellular model for elucidating the altered molecular signature induced by gestational diabetes mellitus in the fetal endothelium. We report that gestational diabetes mellitus impairs fetal human umbilical vein endothelial cells through a mechanism encompassing microRNA-101 and the histone methyltransferase enhancer of zester homolog-2. Interfering with this mechanism improved the gestational diabetes mellitus-human umbilical vein endothelial cells phenotype, suggesting the hypothesis that epigenetic drugs and microRNA-therapeutics might be able to combat the metabolic memory associated with diabetes mellitus.
Significance
